The current status of immunobased therapies for metastatic renal-cell carcinoma.

ABSTRACT: The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent times there have been landmark advances made in the field of specific immunotherapy for a number of malignancies, including kidney cancer. This review outlines the range of immunobased agents currently available for the treatment of mRCC.

SUBMITTER: Sathianathen NJ 

PROVIDER: S-EPMC5723125 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature